Archives
|
Entry
|
Blogger
|
Date
|
Location
|
|
QuantumCor Sees Future of Heart Failure Treatment in No Device Left Behind
|
Luke Timmerman |
11/02/09 |
Seattle
|
|
Celladon CEO Upbeat on Gene Therapy for Heart
|
Denise Gellene |
05/29/09 |
San Diego
|
|
Targeted Genetics, Mainstay of Gene Therapy, Faces Likely Shutdown
|
Luke Timmerman |
05/07/09 |
Seattle
|
|
Targeted Genetics Hands Off Manufacturing
|
Luke Timmerman |
03/02/09 |
Seattle
|
|
Pathway Medical Gets Traction, Ekos Raises $12.5M, ZymoGenetics Sales Boss Departs, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
02/05/09 |
Seattle
|
|
Cardiac Dimensions Wins European Clearance to Sell Device for Heart Failure
|
Luke Timmerman |
01/29/09 |
Seattle
|
|
Seattle Genetics Raises Dough, Trubion Feels Fallout of Pfizer Deal, Novo Sets Up Shop, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
01/29/09 |
Seattle
|
|
NitroMed Takes Buyout Offer from Deerfield, Dumps Archemix at the Altar
|
Ryan McBride |
01/27/09 |
Boston
|
|
Cardiac Dimensions, Fixer of Leaky Hearts, Edges Toward European Market and Pivotal U.S. Test
|
Luke Timmerman |
01/26/09 |
Seattle
|
|
MicroRNA Leaps Ahead: Alnylam-Isis Venture, Regulus, Shows Its Drug Works in Animals With Heart Failure
|
Luke Timmerman |
11/30/08 |
San Diego
|
|
Abiomed To Sell 2.4 Million Shares of Common Stock
|
Luke Timmerman |
08/19/08 |
Boston
|
|
Page 1 of
1 |
|
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2009, Xconomy, Inc.
XCONOMY is a registered service mark of Xconomy, Inc.
All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
